The Biosecurity Core ensures compliance with local, state and national regulations and serves as a resource for pending legislation related to biosecurity in high and maximum containment laboratories and control of select agents. Core staff works closely with the Environmental Health and Biosafety Regulations and Requirements (EH&BRR) Core to develop and implement programs. The Core provides oversight, devises and directs relevant staff training, and develops and implements in conjunction with appropriate UTMB departments a personnel reliability program for BSL4 staff. It assists with the planning and conduct of biosecurity drills in close association with EH&BRR Core. The Core monitors access to select agent inventories and conducts an independent select agent program review. It oversees physical security personnel security, material control and accountability, transport security and information security. It interfaces with the UTMB Police Department, which provides the GNL Security Services, independently implements the physical security program, and is committed to providing the safe and secure operation of the GNL, for both UTMB employees and the surrounding community. The UTMB Police Department complies with all federal and state laws regulating select biological agents.

Public Health Relevance

The Biosecurity Core ensures compliance with all federal and state laws regulating select agents and serves as a resource for pending legislation and federal activities related to biosecurity. The Core oversees physical and personnel security, material control and accountability, transport and information security, and interfaces with the UTMB Police Department, which independently implements the GNL physical security program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI094660-04
Application #
8820993
Study Section
Special Emphasis Panel (ZAI1-PRJ-M (J1))
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
4
Fiscal Year
2014
Total Cost
$1,997,858
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Cross, Robert W; Mire, Chad E; Agans, Krystle N et al. (2018) Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J Infect Dis 218:S448-S452
Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest 127:4437-4448
Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149
Warfield, Kelly L; Warren, Travis K; Qiu, Xiangguo et al. (2017) Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Res 138:22-31
Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374

Showing the most recent 10 out of 59 publications